Principal components analysis of agitation outcomes in Alzheimer's disease

被引：2

作者：

Yesavage, Jerome A. ^{[1
,2
,3
]}

Taylor, Joy L. ^{[1
,2
]}

Friedman, Leah ^{[2
]}

Rosenberg, Paul B. ^{[4
]}

Lazzeroni, Laura C. ^{[2
]}

Leoutsakos, Jeannie-Marie S. ^{[4
]}

Kinoshita, Lisa M. ^{[1
]}

Perlow, Mark J. ^{[1
]}

Munro, Cynthia A. ^{[4
]}

Devanand, D. P. ^{[5
,6
]}

Drye, Lea T. ^{[7
]}

Mintzer, Jacobo E. ^{[8
,9
]}

Pollock, Bruce G. ^{[10
]}

Porsteinsson, Anton P. ^{[11
]}

Schneider, Lon S. ^{[12
]}

Shade, David M. ^{[7
]}

Weintraub, Daniel ^{[13
,14
]}

Lyketsos, Constantine G. ^{[4
]}

Noda, Art ^{[2
]}

机构：

[1] Dept Vet Affairs Hlth Care Syst, Palo Alto, CA 94304 USA

[2] Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, Stanford, CA 94305 USA

[3] Stanford Univ, Sch Med, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA

[4] Johns Hopkins Sch Med, Johns Hopkins Bayview Med Ctr, Dept Psychiat & Behav Sci, Baltimore, MD 21205 USA

[5] New York State Psychiat Inst & Hosp, Div Geriatr Psychiat, New York, NY 10032 USA

[6] Columbia Univ, Coll Phys & Surg, New York, NY 10032 USA

[7] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD 21205 USA

[8] Roper St Francis Healthcare, Clin Biotechnol Res Inst, Charleston, SC 29401 USA

[9] Ralph H Johnson VA Med Ctr, Charleston, SC 29401 USA

[10] Univ Toronto, CAMH, Campbell Inst, Toronto, ON M5S 2S1, Canada

[11] Univ Rochester, Sch Med & Dent, Rochester, NY 14642 USA

[12] Univ So Calif, Keck Sch Med, Los Angeles, CA 90089 USA

[13] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA

[14] Dept Vet Affairs, Philadelphia, PA 19104 USA

来源：

JOURNAL OF PSYCHIATRIC RESEARCH | 2016年 / 79卷

关键词：

Agitation; Alzheimer's disease; Principal component analysis; CITALOPRAM;

D O I：

10.1016/j.jpsychires.2016.04.004

中图分类号：

R749 [精神病学];

学科分类号：

100205 ;

摘要：

Background: We developed a composite measure of agitation as a secondary outcome of change over time in the Citalopram for Agitation in Alzheimer's disease study (CitAD). CitAD demonstrated a positive effect of citalopram on agitation on the Neurobehavioral Rating Scale agitation subscale (NBRS-A). CitAD included additional agitation measures such as the Cohen-Mansfield Agitation Inventory and the Neuropsychiatric Inventory. Methods: We performed principal components analyses on change in individual item of these scales for the same, original CitAD subjects. Results: The first principal component accounted for 12.6% of the observed variance and was composed of items that appear to reflect agitation. The effect size for citalopram calculated using this component was 0.53 (95% CI 0.22-0.83) versus 0.32 for the NBRS-A (95% CI 0.01-0.62). Conclusions: Results suggest that a composite measure of change in agitation might be more sensitive than change in a single primary agitation measure. Published by Elsevier Ltd.

引用

页码：4 / 7

页数：4

共 50 条

[1] Principal components analysis of the neuropsychiatric inventory in Alzheimer's disease
Hollingworth, P
Hamshere, ML
Hill, GT
Moore, PJ
Ludford, RM
Foy, C
Archer, N
Edmondson, A
Proitsi, P
Lynch, A
Evans, I
Hamilton, BA
Lovestone, S
Powell, J
Brayne, C
Rubinsztein, DC
Lawlor, B
Gill, M
Owen, MJ
[J]. NEUROBIOLOGY OF AGING, 2004, 25 : S97 - S97
[2] Disease progression modelling of Alzheimer's disease using probabilistic principal components analysis
Saint-Jalmes, Martin
Fedyashov, Victor
Beck, Daniel
Baldwin, Timothy
Faux, Noel G.
Bourgeat, Pierrick
Fripp, Jurgen
Masters, Colin L.
Goudey, Benjamin
[J]. NEUROIMAGE, 2023, 278
[3] Neuropathological heterogeneity in Alzheimer's disease: A study of 80 cases using principal components analysis
Armstrong, RA
Nochlin, D
Bird, TD
[J]. NEUROPATHOLOGY, 2000, 20 (01) : 31 - 37
[4] Cannabinoids for Agitation in Alzheimer's Disease
Outen, John D.
Burhanullah, M. Haroon
Vandrey, Ryan
Amjad, Halima
Harper, David G.
Patrick, Regan E.
May, Rose L.
Agronin, Marc E.
Forester, Brent P.
Rosenberg, Paul B.
[J]. AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY, 2021, 29 (12): : 1253 - 1263
[5] The use of multivariate methods in the identification of subtypes of Alzheimer's disease: A comparison of principal components and cluster analysis
Armstrong, RA
Wood, L
Myers, D
Smith, CUM
[J]. DEMENTIA, 1996, 7 (04): : 215 - 220
[6] Disentangling the Treatment of Agitation in Alzheimer's Disease
Howard, Robert J.
[J]. AMERICAN JOURNAL OF PSYCHIATRY, 2016, 173 (05): : 441 - 443
[7] Quetiapine and rivastigmine for agitation in Alzheimer’s disease
Raymond L. Ownby
[J]. Current Psychiatry Reports, 2006, 8 (1) : 10 - 10
[8] Commentary on "Cannabinoids for Agitation in Alzheimer's Disease"
Goveas, Joseph S.
[J]. AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY, 2021, 29 (12): : 1264 - 1266
[9] Advancements in the treatment of agitation in Alzheimer's disease
Antonsdottir, Inga M.
Smith, Jessica
Keltz, Melanie
Porsteinsson, Anton P.
[J]. EXPERT OPINION ON PHARMACOTHERAPY, 2015, 16 (11) : 1649 - 1656
[10] Donepezil for the treatment of agitation in Alzheimer's disease
Howard, Robert J.
Juszczak, Edmund
Ballard, Clive G.
Bentham, Peter
Brown, Richard G.
Bullock, Roger
Burns, Alistair S.
Holmes, Clive
Jacoby, Robin
Johnson, Tony
Knapp, Martin
Lindesay, James
O'Brien, John T.
Wilcock, Gordon
Katona, Cornelius
Jones, Roy W.
DeCesare, Julia
Rodger, Michaela
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (14): : 1382 - 1392

← 1 2 3 4 5 →